Perceptive Advisors LLC Acquires 617,000 Shares of Roivant Sciences Ltd. $ROIV

Perceptive Advisors LLC grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 8.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,985,461 shares of the company’s stock after purchasing an additional 617,000 shares during the quarter. Roivant Sciences makes up about 3.1% of Perceptive Advisors LLC’s portfolio, making the stock its 6th biggest holding. Perceptive Advisors LLC’s holdings in Roivant Sciences were worth $173,285,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TD Asset Management Inc boosted its stake in Roivant Sciences by 94.7% during the 3rd quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock worth $4,784,000 after purchasing an additional 153,800 shares during the last quarter. HighVista Strategies LLC boosted its stake in Roivant Sciences by 61.4% during the 3rd quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock worth $1,496,000 after purchasing an additional 37,590 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Roivant Sciences during the 3rd quarter worth $877,000. Pictet Asset Management Holding SA boosted its stake in Roivant Sciences by 790.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after purchasing an additional 2,052,693 shares during the last quarter. Finally, Capricorn Fund Managers Ltd boosted its stake in Roivant Sciences by 124.4% during the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock worth $9,667,000 after purchasing an additional 247,000 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ROIV shares. HC Wainwright reaffirmed a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. Sanford C. Bernstein initiated coverage on Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 price target on the stock. Leerink Partners set a $42.00 price target on Roivant Sciences in a report on Thursday, May 21st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.59.

Insider Activity at Roivant Sciences

In related news, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the sale, the chief accounting officer directly owned 84,191 shares in the company, valued at approximately $2,388,498.67. The trade was a 13.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $48,827,417.01. This trade represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 703,312 shares of company stock worth $20,805,883. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Up 2.6%

NASDAQ ROIV opened at $31.20 on Thursday. Roivant Sciences Ltd. has a 52 week low of $10.70 and a 52 week high of $32.79. The business’s fifty day simple moving average is $29.10 and its 200-day simple moving average is $26.22. The firm has a market cap of $22.44 billion, a PE ratio of -52.00 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter in the previous year, the firm earned ($0.29) EPS. Research analysts expect that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.